Core Viewpoint - A securities fraud class action lawsuit has been filed against agilon health, inc. on behalf of investors who acquired its securities during the specified Class Period, following significant stock price decline due to leadership changes and missed financial estimates [1][2]. Group 1: Company Developments - On August 4, 2025, agilon announced the departure of its President, CEO, and Director, which was classified as a termination without cause under his employment agreement [2]. - The company released its second quarter 2025 financial results on the same day, which missed estimates and led to the suspension of its 2025 guidance due to leadership changes and ongoing market uncertainties [2]. Group 2: Stock Performance - Following the announcement of leadership changes and poor financial results, agilon's stock price dropped by $0.93, or 51.5%, closing at $0.88 per share on August 5, 2025 [2]. Group 3: Allegations in the Lawsuit - The lawsuit alleges that during the Class Period, agilon's management made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects [3]. - Specific allegations include that management issued guidance for 2025 that was known or should have been known to be unachievable due to industry headwinds, and that they overstated the financial impact of strategic actions taken to reduce risk [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against agilon health, inc. due to allegations of violations of federal securities laws, particularly regarding misleading statements and guidance related to the company's financial performance [4][6]. Company Overview - Agilon health, inc. is publicly traded on the NYSE under the ticker AGL [4]. - The company has faced significant challenges, leading to a suspension of its previously issued full-year 2025 financial guidance [7]. Allegations and Legal Actions - The complaint against agilon health alleges that the company and its executives made false or misleading statements, including: 1. Recklessly issuing guidance for 2025 that was unlikely to be achieved due to known industry headwinds [6]. 2. Overstating the immediate positive financial impact from strategic actions taken to reduce risk [6]. 3. Providing materially false or misleading statements about the company's business and prospects [6]. - Following the release of disappointing second-quarter results on August 4, 2025, agilon health's stock plummeted by 51.5% on August 5, 2025 [7]. Class Action Details - A federal securities class action has been filed against agilon health, with a deadline of March 2, 2026, for investors to seek the role of lead plaintiff [4]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [8]. Call for Information - Faruqi & Faruqi encourages anyone with information regarding agilon health's conduct, including whistleblowers and former employees, to come forward [9].

Core Viewpoint - A class action securities lawsuit has been filed against agilon health, inc. for alleged securities fraud affecting investors between February 26, 2025, and August 4, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements and concealed information regarding the company's 2025 guidance, which they allegedly knew was unattainable due to industry challenges [2] - It is alleged that defendants overstated the financial benefits from strategic actions taken by agilon to mitigate risks, leading to materially false and misleading statements about the company's business and prospects [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 2, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 20 years of experience [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against agilon health, inc. due to alleged violations of federal securities laws, particularly related to misleading statements and guidance regarding financial performance [2][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in agilon health to contact them directly to discuss their legal options [1]. - A federal securities class action has been filed against agilon health, with a deadline of March 2, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that agilon health and its executives made false statements and failed to disclose significant industry challenges that would impact financial guidance for 2025 [5]. Group 2: Financial Performance and Market Reaction - On August 4, 2025, agilon health reported its second-quarter results, indicating that industry headwinds were more severe than previously anticipated, leading to the suspension of its full-year 2025 financial guidance [6]. - Following the announcement, agilon health's stock experienced a significant decline of 51.5% on August 5, 2025 [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a prominent national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

Core Viewpoint - A class action lawsuit has been filed against Agilon Health, Inc. concerning allegations of securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP for participation in the class action, with a deadline to apply as Lead Plaintiff by March 2, 2026 [2]. - The lawsuit pertains to actions taken by Agilon and certain officers or directors that may have violated securities laws [2]. Group 2: Company Background and Recent Events - On August 4, 2025, Agilon announced the resignation of Steven Sell as President, CEO, and Director, coinciding with the release of its second-quarter financial results [4]. - The Executive Chair of Agilon indicated that industry challenges were more severe than anticipated, leading to the suspension of the company's full-year 2025 financial guidance [4]. - Following these announcements, Agilon's stock price dropped by $0.94, or 51.52%, closing at $0.88 per share on August 5, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against agilon health, inc. for securities fraud, following a significant drop in stock price after the announcement of leadership changes and missed financial estimates [1][3]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of shareholders who purchased agilon securities between February 26, 2025, and August 4, 2025, with a deadline of March 2, 2026, for filing a lead plaintiff motion [1]. - The lawsuit alleges that agilon's management made materially false and misleading statements regarding the company's business and financial outlook during the class period [4]. Group 2: Financial Impact - On August 4, 2025, agilon announced the departure of its President, CEO, and Director, which was classified as a termination without cause, leading to a suspension of its 2025 guidance [3]. - Following this announcement, agilon's stock price plummeted by $0.93, or 51.5%, closing at $0.88 per share on August 5, 2025, resulting in significant losses for investors [3]. Group 3: Allegations Against Management - The complaint claims that management recklessly issued guidance for 2025, despite being aware of material industry challenges that would prevent achieving those targets [4]. - It is alleged that management overstated the financial benefits from strategic actions taken to mitigate risks, rendering their positive statements about the company's prospects misleading [4].

Core Viewpoint - A class action lawsuit has been filed against agilon health, inc. for allegedly making false statements and failing to disclose critical information regarding its financial guidance and strategic actions during the class period from February 26, 2025, to August 2, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that agilon issued guidance for 2025 that it knew or should have known was unattainable due to significant industry challenges [1] - It is alleged that agilon materially overstated the immediate positive financial impact from its strategic actions aimed at reducing risk [1] - Investors who suffered losses on their agilon investments have until March 2, 2026, to request lead plaintiff appointment [1] Group 2: Leadership Transition and Financial Results - On August 4, 2025, agilon announced the resignation of Steven Sell as President, CEO, and Director, which was classified as a termination without cause [2] - The company suspended its previously issued full-year 2025 financial guidance, acknowledging that industry headwinds were more severe than anticipated [2] - Following this announcement, agilon's share price fell by $0.94, approximately 51.6%, from $1.82 to $0.88 [2] Group 3: Lead Plaintiff Appointment Process - The federal securities laws allow any investor who acquired eligible securities during the class period to seek appointment as lead plaintiff in the class action lawsuit [3] - Courts typically appoint investors with the largest financial loss rather than those with the largest investment portfolio [3] - Lead plaintiffs have significant influence over case strategy, settlement decisions, and allocation of settlement funds among class members [3]

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Agilon Health, Inc. for alleged misrepresentations regarding the company's guidance for 2025, affecting investors who purchased securities between February 26, 2025, and August 4, 2025 [1][3]. Group 1 - The lawsuit is on behalf of investors who acquired Agilon securities during the specified period [1]. - The defendants are accused of making misrepresentations related to the company's issued guidance for 2025 [3]. - Investors interested in joining the class action or discussing their legal rights can contact the Investor Relations Manager [3][4]. Group 2 - The deadline to file papers to serve as lead plaintiff is March 2, 2026, and participation as a lead plaintiff is not required to share in any recovery [4]. - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has represented both individual investors and large pension funds [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased agilon health, inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased agilon securities between February 26, 2025, and August 4, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 2, 2026 [3]. - The lawsuit alleges that defendants made false and misleading statements regarding agilon's financial guidance and the impact of strategic actions taken to reduce risk, which led to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against agilon health, inc. due to alleged violations of federal securities laws, encouraging affected investors to contact them for legal options [2][5]. Group 1: Legal Investigation - The law firm is looking into claims against agilon health, reminding investors of a deadline on March 2, 2026, to seek the role of lead plaintiff in a federal securities class action [2]. - The complaint alleges that agilon health and its executives made false or misleading statements regarding the company's financial guidance for 2025, which they knew was unattainable due to industry challenges [5]. Group 2: Financial Impact - On August 4, 2025, agilon health announced the suspension of its full-year 2025 financial guidance, leading to a significant stock price drop of 51.5% on August 5, 2025 [6]. - The company’s Executive Chair acknowledged that industry headwinds were more severe than previously anticipated, impacting the company's financial outlook [6]. Group 3: Investor Communication - Faruqi & Faruqi encourages anyone with information regarding agilon health's conduct, including whistleblowers and former employees, to reach out to the firm [8].